Background {#Sec1}
==========

Blood pressure is a strong risk factor for cardiovascular disease (CVD) \[[@CR1], [@CR2]\] and chronic kidney disease (CKD) \[[@CR3]--[@CR5]\]. Among patients with diabetes, hypertension is associated with the incidence of CVD and CKD as well \[[@CR6]--[@CR9]\]. The reduction of blood pressure could reduce the risks both for CVD and CKD.

Obesity, especially increased visceral adiposity is a major cause of hypertension, accounting for 65--75 % of the risk for human essential hypertension \[[@CR10]\]. In addition, obesity has been reported to be associated with various cardio-metabolic risks including insulin resistance and dyslipidemia, and also be directly associated with CVD \[[@CR11]--[@CR14]\]. Furthermore, abdominal obesity is a strong risk factor for CKD both in general population and patients with diabetes \[[@CR15], [@CR16]\]. Therefore, abdominal adiposity is thought to be an important determinant that can account for the association of cardio-metabolic risks with CVD and CKD.

Regarding the association between blood pressure and CVD, the impact of elevated blood pressure on CVD events has been reported to be stronger among people without obesity than those with \[[@CR17]--[@CR19]\]. Also, it has been suggested that normal-weight patients with essential hypertension have increased arterial stiffness \[[@CR20]\] and systemic vascular resistance. We recently reported that increased visceral adiposity with normal weight is strongly associated with cardio-metabolic risks and arterial stiffness in patients with type 2 diabetes \[[@CR21]\]. These studies imply that visceral adiposity could modify the impact of blood pressure on CVD; however, it is uncertain whether increased blood pressure could more strongly affect arterial stiffening in people with low visceral adiposity than in those with high visceral adiposity. On the other hand, among obese people, especially those with high visceral adiposity, intra-renal renin-angiotensin-aldosterone system is activated \[[@CR22]--[@CR24]\], leading to the glomerular hyperfiltration at the early stage of obesity-hypertension. Hyperglycemia also induces renal damage directly or through hemodynamic modifications including glomerular hyperfiltration \[[@CR25]\]. Therefore, it is possible that increase in systemic blood pressure could more strongly affect the renal hemodynamics in obese, especially in obese patients with diabetes, than in non-obese people, resulting in more severe renal manifestations such as increased albuminuria and decreased glomerular filtration rate (GFR). Taken together, we conducted this cross-sectional study to investigate the interaction of visceral adiposity with blood pressure on the increased risk for arterial stiffening and albuminuria in patients with type 2 diabetes.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Patients with type 2 diabetes who admitted to Tokyo Medical and Dental University Hospital for the purpose of glycemic control and/or evaluation of diabetic complications participated in this cross-sectional study. Patients were eligible, if they were aged ≥20 years, and patients who measured both brachia-ankle pulse wave velocity (ba-PWV) and visceral fat area (VFA) and subcutaneous fat area (SFA) by a dual bioelectrical impedance analyzer were enrolled. Patients with severe renal impairment (estimated glomerular filtration rate \[eGFR\] \<15 mL/min/1.73 m^2^ or undergoing renal replacement therapy), pregnant women, and those with infectious or malignant diseases were excluded. Type 2 diabetes was diagnosed according to the criteria of the Japan Diabetes Society (JDS) \[[@CR26]\]. As shown in Fig. [1](#Fig1){ref-type="fig"}, 638 patients were finally enrolled in this study. This study complies with the principles laid by Declaration of Helsinki and has been approved by the ethical committee of Tokyo Medical and Dental University (No. 1924).Fig. 1Flowchart of patient recruitment to the study

Clinical and biochemical analysis {#Sec4}
---------------------------------

Standardized questionnaires were used to obtain information on smoking, medication and past history. Smoking history was classified as either current smoker or non-smoker. CVD was defined as the presence of a previous stroke, myocardial infarction, coronary revascularization procedure. Blood pressure was measured in the sitting position after at least 5 min rest, using an electronic sphygmomanometer (ES-H55, Terumo Inc., Tokyo, Japan). HbA1c was measured by the latex agglutination method. HbA1c levels were expressed in accordance with the National Glycohemoglobin Standardization Programs recommended by the Japanese Diabetes Society \[[@CR26]\]. Urinary albumin (UAE) and creatinine excretion were measured by the turbidimetric immunoassay and enzymatic method, respectively, in a single 24-h urine collection. GFR was estimated using the following equation for the Japanese, as proposed by the Japanese Society of Nephrology \[[@CR27]\]; GFR = 194 × SCr^−1.094^ × age^−0.287^ \[(if female) × 0.739\], where SCr stands for serum creatinine in mg/dl, measured by an enzymatic method. Coefficient of variation of R--R intervals (CV-RR) was used for the assessment of diabetic neuropathy. BMI was calculated as weight divided by the square of height (kg/m^2^). VFA and SFA were measured at the level of umbilicus by dual bioelectrical impedance analyzer (DUALSCAN, Omron Healthcare Co., Kyoto, Japan). Patients were divided into those with VFA \< 100 cm^2^ (low-V) and those with VFA ≥ 100 cm^2^ (high-V). Brachial-ankle pulse wave velocity (ba-PWV) was measured using a volume-plethysmographic apparatus (BP-203RPE II form PWV/ABI, Omron Healthcare Co., Kyoto, Japan), with subjects in the supine position after at least 5 min of rest \[[@CR28], [@CR29]\]. The ba-PWV was calculated as reported previously \[[@CR30]\]. We simultaneously measured ba-PWV on both the right and left sides and the averaged values from each individual were subjected to statistical analysis.

Statistical analysis {#Sec5}
--------------------

Statistical analysis was performed using programs available in the SPSS version 21.0 statistical package (SPSS Inc., Chicago, IL, USA). Data are presented as mean ± SD, median with interquartile range (IQR), or percent as appropriate according to data distribution. Normality was tested by the Kolmogorov--Smirnov test. Differences between low-V and high-V patients were tested with a *t* test or Mann--Whitney U test for continuous variables and Chi square test for categorical variables. Linear regression analyses were used to investigate the association of SBP and VFA with ba-PWV and UAE. We determined the linear relationship and multicollinearity for regression assumptions. We removed one variable if a strong correlation (coefficient of correlation \>0.8) was observed between the two independent variables. In order to check the multicollinearity, we evaluated variance infiltration factors. If multicollinearity was found in the data, one variable was removed from the multivariate regression analysis. The following covariates were incorporated into the analysis with a stepwise procedure; duration of diabetes, smoking status, triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, HbA1c, eGFR, log CRP and the usage of insulin, calcium channel blockers (CCB), angiotensin receptor blockers (ARB), statins and anti-platelet agents. Age and gender were forced into the model. The interaction between SBP and VFA was also investigated in the multiple linear regression analyses. Differences were considered to be statistically significant at p value less than 0.05.

Results {#Sec6}
=======

Clinical characteristics of patients with low-V and high-V {#Sec7}
----------------------------------------------------------

Among 638 patients, 341 and 297 were classified as low-V and high-V patients. As shown in Table [1](#Tab1){ref-type="table"}, high-V patients were significantly younger, had significantly higher SBP and DBP, lower HDL-C, higher triglycerides levels and a shorter duration of diabetes than the low-V patients. Urinary C-peptide and UAE levels in high-V patients were significantly higher than those in low-V patients. BMI, WC, VFA and SFA levels in high-V patients were significantly higher than in those with low-V. The high-V patients were more frequently receiving CCBs, ARBs and statin therapy and were less likely to receive insulin than low-V patients. baPWV in high-V patients was significantly lower than that in low-V patients.Table 1Clinical characteristics according to VFA levelsVFA \< 100 cm^2^ (N = 341)VFA ≥ 100 cm^2^ (N = 297)p valuesAge (years)66 ± 1262 ± 13\<0.001Gender (% male)57630.196SBP (mmHg)128 ± 20132 ± 170.016DBP (mmHg)73 ± 1278 ± 12\<0.001HbA1c (mmol/mol)71.6 ± 20.275.0 ± 19.50.029HbA1c (%)8.7 ± 1.89.0 ± 1.8HDL-cholesterol (mmol/l)1.32 ± 0.421.19 ± 0.31\<0.001LDL-cholesterol (mmol/l)2.87 (2.29--3.56)2.79 (2.26--3.44)0.515Triglycerides (mmol/l)1.31 (0.98--1.86)1.61 (1.19--2.26)\<0.001Urinary C-peptide (μg/day)42 (27--67)60 (35--99)\<0.001Duration of diabetes (years)12 (5--20)10 (4--16)0.044Current smoker (%)22250.452History of CVD13170.183UAE (mg/day)11 (7--26)19 (10--58)0.001eGFR (ml/min/1.73 m^2^)72.0 ± 23.371.5 ± 25.60.791AST (U/l)22 (17--28)24 (19--41)\<0.001ALT (U/l)19 (14--30)28 (18--48)\<0.001C-reactive protein (mg/l)0.80 (0.40--1.95)1.60 (0.80--3.60)\<0.001PDR (%)19120.536CV-RR (%)3.3 (2.2--4.8)3.6 (2.3--5.3)0.109ba-PWV (cm/s)1711 (1459--1906)1582 (1411--1785)0.007Body mass index (kg/m^2^)23.5 ± 3.229.4 ± 4.4\<0.001Waist circumference (cm)86 ± 9102 ± 11\<0.001Visceral fat area (cm^2^)74 (57--87)133 (114--152)\<0.001Subcutaneous fat area (cm^2^)144 (120--178)236 (194--284)\<0.001Insulin (%)75610.002CCBs (%)29390.023ARBs (%)3553\<0.001Statin (%)42520.050Anti-platelets (%)17220.322*ALT* alanine aminotransferase, *ARB* angiotensin receptor blocker, *AST* asparatate aminotransferase, *baPWV* brachial-ankle pulse wave velocity, *CCB* calcium channel blocker, *CVD* cardiovascular disease, *CV-RR* coefficient of variation of R--R intervals, *DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate, *HDL* high-density lipoprotein, *LDL* low-density lipoprotein, *PDR* proliferative diabetic retinopathy, *SBP* systolic blood pressure

Association between SBP and baPWV according to VFA categories {#Sec8}
-------------------------------------------------------------

Table [2](#Tab2){ref-type="table"} shows the linear regression analyses to investigate the association between SBP and ba-PWV in patients with low-V and those with high-V. In the univariate model, SBP was significantly and equivalently associated with ba-PWV. After adjusting for age and gender, the statistical significance of SBP with ba-PWV was unchanged both in patients with low-V and those with high-V. In the multivariate model including covariates such as eGFR and anti-hypertensive agents, the association of SBP with ba-PWV remained significant regardless of visceral adiposity (standardized β 0.224, p = 0.001 in low-V and standardized β 0.196, p = 0.004 in high-V). Among patients with high-V, SFA was inversely associated with ba-PWV (standardized β −0.199, p = 0.007). eGFR was a significant covariate regardless of visceral adiposity.Table 2Linear regression analysis to investigate the association of blood pressure and visceral adiposity with arterial stiffness in patients with type 2 diabetesVFA \< 100 cm^2^VFA ≥ 100 cm^2^Standardized βp valuesStandardized βp valuesUnivariate Systolic blood pressure0.1830.0010.215Age- and gender-adjusted Systolic blood pressure0.1720.0010.253 Age0.426\<0.0010.421 Gender (male versus female)0.0710.1510.044Multivariate Systolic blood pressure0.2240.0010.1960.004 Age0.430\<0.0010.383\<0.001 Gender (male versus female)0.1300.0510.0070.920 eGFR−0.0870.055−0.1990.042 SFANA0.1490.007 CCBNA−0.1550.031*CCB* calcium channel blocker, *eGFR* estimated glomerular filtration rate, *SFA* subcutaneous fat area, *VFA* visceral fat area

Association between SBP and UAE according to VFA categories {#Sec9}
-----------------------------------------------------------

Table [3](#Tab3){ref-type="table"} shows the association between SBP and UAE according to VFA categories among patients with type 2 diabetes. In the univariate model, SBP was significantly associated with UAE both in patients with low-V and those with high-V. The association of SBP with UAE was unchanged in age- and gender-adjusted model regardless of visceral adiposity (standardized β 0.205, p = 0.001 in patients with low-V and standardized β 0.290, p \< 0.001 in patients with high-V). In the multivariate model adjusting for covariates including age, gender, diabetic complications such as neuropathy and retinopathy and HbA1c level, SBP remained significantly associated with UAE in patients with high-V (standardized β 0.263, p = 0.001); whereas, its association with UAE was attenuated in those patients with low-V (standardized β 0.140, p = 0.080).Table 3Linear regression analysis to investigate the association of blood pressure and visceral adiposity with albuminuria in patients with type 2 diabetesVFA \< 100 cm^2^VFA ≥ 100 cm^2^Standardized βp valuesStandardized βp valuesUnivariate Systolic blood pressure0.2030.0010.280\<0.001Age- and gender-adjusted Systolic blood pressure0.2050.0010.290\<0.001 Age0.0790.1880.1720.172 Gender (male versus female)0.0740.2190.0870.087Multivariate Systolic blood pressure0.1400.0800.2630.001 Age−0.0420.649−0.0900.236 Gender (male versus female)0.1200.1220.1660.28 eGFR−0.1910.042NA Insulin0.1450.064NA PDR0.1720.024NA CV-RR−0.1420.075−0.1610.034 HbA1c0.1350.076*CV-RR* Coefficient of variation of RR intervals, *eGFR* estimated glomerular filtration rate, *PDR* proliferative diabetic retinopathy, *VFA* visceral fat area

Interaction between SBP and VFA accounting for the risk of arterial stiffening and albuminuria {#Sec10}
----------------------------------------------------------------------------------------------

Table [4](#Tab4){ref-type="table"} shows the multivariate linear regression analyses to investigate whether binary interaction between SBP and VFA could account for the risks of arterial stiffening and albuminuria in the whole cohort. The significant interaction between SBP and VFA was observed in the model where UAE was used for a dependent variable; whereas, no significant interaction of SBP with VFA was found as for ba-PWV.Table 4Interaction between blood pressure and visceral adiposity accounting for the risk of arterial stiffening and albuminuria in patients with type 2 diabetesba-PWVUAEStandardized βp valuesStandardized βp valuesSBP × VFA−0.0080.9160.1720.040Systolic blood pressure0.177\<0.0010.1710.001Visceral fat area0.1490.149−0.0600.471Age0.430\<0.001NABody mass index−0.2990.001NAeGFR−0.1460.008NACalcium channel blocker0.1090.029NAHbA1cNA−0.1380.009CV-RRNA0.1480.005Gender (male versus female)NA0.1300.015Angiotensin receptor blockerNA0.1140.030InsulinNA0.1090.035*ba-PWV* brachial-ankle pulse wave velocity, *CV-RR* Coefficient of variation of RR intervals, *eGFR* estimated glomerular filtration rate, *SBP* systolic blood pressure, *UAE* urinary albumin excretion, *VFA* visceral fat area

Discussion {#Sec11}
==========

Both increased arterial stiffness and albuminuria are strong predictors for mortality, CVD and CKD in patients with diabetes \[[@CR31]--[@CR36]\]. Therefore, it is important to elucidate the high risk groups both for increased arterial stiffness and albuminuria among diabetic patients. This study clearly demonstrates that increased SBP can equivalently account for the risk for arterial stiffening regardless of visceral adiposity; whereas, the impact of SBP on albuminuria is stronger in diabetic patients with high visceral adiposity than those with low visceral adiposity.

Association of blood pressure and visceral adiposity with organ damage {#Sec12}
----------------------------------------------------------------------

Visceral adiposity has been reported to be associated with incident hypertension \[[@CR37], [@CR38]\] and albuminuria \[[@CR39], [@CR40]\]. More recently, we found that high visceral fat with low subcutaneous fat accumulation is an important determinant of carotid atherosclerosis and high subcutaneous fat could be protective against atherosclerosis in patients with type 2 diabetes \[[@CR41]\], and others reported that subcutaneous fat thickness assessed by ultrasound is inversely associated with carotid atherosclerosis in diabetic patients, particularly in men \[[@CR42]\]. Moreover, visceral adiposity is strongly associated with the alteration of myocardial glucose uptake and its association further relates to type 2 diabetes \[[@CR43]\]. These studies suggest that visceral and subcutaneous adiposities are directly associated not only cardio-metabolic risks but also target organ damage including heart and arterial wall injuries. We found in this study a stronger association of blood pressure with albuminuria in patients with high visceral adiposity than those with low visceral adiposity, suggesting that visceral adiposity could modify the association of blood pressure at least with albuminuria in patients with type 2 diabetes.

Potential mechanisms regarding the interaction between blood pressure and adiposity on albuminuria {#Sec13}
--------------------------------------------------------------------------------------------------

By which mechanisms are involved in the greater impact of elevated blood pressure on albuminuria in patients with high visceral adiposity than in those with low visceral adiposity? Sympathetic activity and local (renal) renin-angiotensin-aldosterone system could account for the association. Obesity increases sympathetic activity in the kidneys and skeletal muscle; however, cardiac sympathetic activity may not be elevated \[[@CR44]--[@CR46]\]. Furthermore, excessive weight gain, especially visceral adiposity increases leptin level, promotes renal compression, activates renal renin-angiotensin-aldosterone system \[[@CR47]\], all of which could impair renal-pressure natriuresis, increase glomerular pressure, leading to progression of albuminuria. These observations could at least partly explain why elevated blood pressure is more strongly associated with albuminuria among patients with high visceral adiposity than among patients with low visceral adiposity.

Strengths and limitations {#Sec14}
-------------------------

The strength of our study is that we directly measured VFA by a dual-impedance analyzer for the assessment of visceral adiposity. Previous studies assessed the interaction of adiposity with the association between hypertension and CVD using BMI or WC \[[@CR7], [@CR8], [@CR48]\]. Thus, to the best our knowledge, this study is the first to investigate the interaction of visceral adiposity directly measured and blood pressure both with arterial stiffness and albuminuria. This study has a couple of limitations that should be mentioned. First, it has recently been reported that absolute loss of visceral fat mass may play a major role in resolution of diabetes following bariatric surgery, regardless of the amount of weight loss \[[@CR49]\], suggesting the importance of prospectively evaluating the change in visceral adiposity to investigate the association between cardio-metabolic risks including blood pressure and organ damage such as arterial stiffening and albuminuria; however, it is impossible to infer causality because of its cross-sectional design. Second, population in this study was ethnically and socially homogeneous, because this study was hospital-based; therefore, generalization of our findings might be limited. Third, we were unable to obtain information on renin-angiotensin-aldosterone system and sympathetic activity. Fourth, we were unable to obtain any information on diet including vitamin A which may reduce visceral fat \[[@CR50]\]. Finally, it is to be elucidated whether the association of blood pressure with arterial stiffness and albuminuria could be mediated by visceral adiposity in populations other than diabetic patients.

Conclusion {#Sec15}
==========

The effect of increased blood pressure on arterial stiffness is almost similar in type 2 diabetic patients with both low and high visceral adiposity, while its association with albuminuria is stronger in the latter.
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